The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.HEIDELBERG, Germany, March 22, 2022 / B3C newswire / Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister.
Lars Hufnagel will be responsible for advancing VERAXA’s antibody screening and ADC technologies by further developing its droplet-based microfluidic screening technology.HEIDELBERG, Germany, March 14, 2022 / B3C newswire / Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, base.
Search jobs VERAXA Biotech and Quadira Biosciences Enter Partnership on ADC Development
HEIDELBERG, Germany and ZUG, Switzerland, June 14, 2021 / B3C newswire / VERAXA Biotech GmbH (former Velabs Therapeutics GmbH), a leading company in innovative ADC engineering and functional antibody screening, announced today that it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the treatment of oncological conditions. The collaboration will leverage both the advantages of VERAXA s advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with Quadira’s superior 3D cellular assay and assessment systems. The agreement provides that VERAXA will be entitled to upfront payments and royalties from the worldwide sale of products resulting from the collaboration. Further details of the agreement were not disclosed.
Xlife Sciences AG: Exit of a project company
More than 20 million euros transaction completed
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.
Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the tec